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Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is a variably severe neu-
romuscular disorder for which no effective treatment is available. Although a number of genes have been
identified in which mutations can cause NM, the pathogenetic mechanisms leading to the phenotypes are
poorly understood. To address this question, we examined gene expression patterns in an NM mouse
model carrying the human Met9Arg mutation of alpha-tropomyosin slow (Tpm3). We assessed five different
skeletal muscles from affected mice, which are representative of muscles with differing fiber-type compo-
sitions, different physiological specializations and variable degrees of pathology. Although these same
muscles in non-affected mice showed marked variation in patterns of gene expression, with diaphragm
being the most dissimilar, the presence of the mutant protein in nemaline muscles resulted in a more similar
pattern of gene expression among the muscles. This result suggests a common process or mechanism oper-
ating in nemaline muscles independent of the variable degrees of pathology. Transcriptional and protein
expression data indicate the presence of a repair process and possibly delayed maturation in nemaline
muscles. Markers indicative of satellite cell number, activated satellite cells and immature fibers including
M-Cadherin, MyoD, desmin, Pax7 and Myf6 were elevated by western-blot analysis or immunohistochemistry.
Evidence suggesting elevated focal repair was observed in nemaline muscle in electron micrographs. This
analysis reveals that NM is characterized by a novel repair feature operating in multiple different muscles.
INTRODUCTION
In recent years, microarray studies have shed light on global
gene expression patterns in a number of different neuromuscu-
lar disorders (1–6). Analysis of human clinical material,
coupled with studies of murine models of various muscular
dystrophies and myopathies, is leading to a new appreciation
of the transcriptional basis for a variety of neuromuscular phe-
notypes. The ultimate goal remains the recognition of primary
and secondary transcriptional and translational changes that
occur during the course of the disease, and the determination
of molecular pathways that will constitute promising thera-
peutic targets. Nemaline myopathy (NM) is one of the
conditions starting to be explored at the transcriptional level.
A slowly or non-progressive congenital myopathy, NM, is
characterized by the presence of nemaline rods in affected
muscle fibers, muscle weakness and absence of muscle regen-
eration. The clinical phenotype, muscle histology and gene
mutations can be quite variable. Different forms of NM can
range from severe neonatal lethal to mild adult onset, and his-
tologically, there is a variation in the number, size and
location of nemaline rods, as well as in the percentage of
fast and slow fibers in affected muscles (7). Mutations have
been described in five different genes that encode skeletal
muscle thin filament proteins: alpha-skeletal muscle
actin (ACTA1), nebulin (NEB), beta-tropomyosin (TPM2),
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alpha-tropomyosin slow (TPM3) and slow troponin T
(TNNT1) (8). No absolute correlations exist between gene
mutations and disease severity or any other phenotypic charac-
teristic. However, gene expression analysis of a heterogeneous
group of NM patients, in terms of disease severity, age and
histology (none of whom had TPM3 mutations), revealed
consistent changes in muscle energy metabolism (reduced),
fibrosis (increased) and evidence for a partial regenerative
response (5).
TPM3 mutations are a rare cause of NM in humans, count-
ing for 2–3% of cases (9–11). A mouse model of
TPM3-related NM was recently generated by transgenic over-
expression of a dominant negative mutation of this gene
(Met9Arg) (10,12). Because most mouse muscles have a
higher proportion of fast fibers (90%) compared with
humans (33%), aTmslow(Met9Arg) was linked to the
human skeletal actin (HSA) promoter that drives expression
preferentially in 2B fibers of the mouse (13). The transgenic
mice presented with all the main characteristics of NM as
described for humans, including nemaline rods, increased
slow/oxidative fiber content and muscle weakness, and there-
fore, to a large extent, they represent a phenocopy of the
human condition. aTmslow(Met9Arg) mice exhibit a non-
progressive increase in slow type 1 fibers and hypertrophy
of fast type 2B fibers during the first few months, followed
by the onset of muscle weakness at 7 months of age. Nemaline
rods are located at the center and periphery of muscle fibers,
and they commonly cluster around the Z-line in a similar
fashion to the rods of patients with the TPM3(Met9Arg)
mutation. The percentage of rod containing fibers increases
between 2 and 12 months of age and varies considerably
between different muscles. However, transgenic mice do not
have an overt clinical phenotype, which is consistent with
the mild form of the disease exhibited by patients carrying
the TPM3(Met9Arg) mutation. In contrast to human
muscles, cytoplasmic bodies and tubular aggregates were
observed in the mouse superficial gastrocnemius, but not in
any of the other mouse muscles examined.
The availability of a mouse model for NM provides a flex-
ible and easily accessible system where multiple different
skeletal muscles can be studied, sufficient amounts of tissue
can be obtained and different therapeutic approaches can even-
tually be evaluated. To investigate the molecular pathways
affected in the muscles of aTmslow(Met9Arg) mice, we ana-
lyzed the gene expression patterns of 12 488 genes and
ESTs (U74Av2 Affymetrix GeneChips) in five different
muscles: tibialis anterior (TA), gastrocnemius (GAS),
plantaris (PLT), diaphragm (DIA) and extensor digitorum
longus (EDL). Variation between the number of fibers with
rods and the percent of slow/fast fibers in different muscles
of the HSA-aTmslow(Met9Arg) mice warrants the study of a
range of muscles (12). The specific muscles were chosen so
as to include muscles presenting with varying levels of pathol-
ogy and usage (e.g. DIA is a muscle in constant motion) while
focusing on distal muscles, as TPM3 Met9Arg NM has a distal
phenotype. Although, significant differences were seen in the
transcriptional ‘response’ of different muscles to the mutation,
the gene expression profiles of the different nemaline muscles
were more similar to each other than between the same
muscles in wild-type mice. Current findings are compared
and contrasted with observations on human NM specimens.
The data indicate an abrogation of normal muscle maturation
and suggest the presence of focal muscle repair as key features
of NM. Future studies will need to address whether focal
repair is indeed a feature consistently present in the
HSA-aTmslow(Met9Arg) mice and human patients.
RESULTS
To examine the transcriptional basis for the form of NM
observed in aTmslowMet9Arg (‘NM’) mice, we conducted
microarray analysis of three or four replicate total RNA
pools from five different muscles (TA, PLT, GAS, DIA and
EDL) each of NM and wild-type (‘WT’) control littermates.
A total of 36 pools were analyzed, each of which contained
RNA from three to five replicate littermates between 7 and
10 months of age. Labeled cRNA targets were hybridized to
Affymetrix U74Av2 GeneChips, resulting in data for 12 488
annotated genes and ESTs.
Correlation coefficient analysis
The correlation coefficients (r) for gene expression signals
between all 36 mouse muscle pools (WT and NM) were calcu-
lated and the averages thereof were used to create a matrix of
correlations between each of the 10 muscle/disease-state point
(Fig. 1). The average r between all WT samples ranged from
0.77 (DIA-WT versus TA-WT) to 0.97 (different PLT-WT
pools), whereas NM samples alone had an average r range
Figure 1. Correlation coefficients for all pairwise comparisons of data sets containing 12 488 probe set signals averaged for each muscle type/state. Heat map
correlates with r-values in increments of 0.05. The DIA in WT (denoted ‘-WT’) mice is most dissimilar to the other skeletal muscles. NM transgenic (denoted
‘-NM’) DIA is more similar not only to other NM muscles but also to the other WT muscles.











from 0.88 (DIA-NM versus TA-NM) to 0.98 (different
GAS-NM pools). The data sets from four of the five muscle
types had high correlations with each other both in the WT
and the NM state. DIA, however, was the exception with the
lowest correlations to all other samples in its WT state. It is
unlikely that this is associated with fiber-type differences
between WT and NM DIA, as there were no significant
expression changes in fast- or slow-fiber genes. Unexpectedly,
NM DIA had higher correlations to all other WT and NM
muscles than WT DIA.
The average r between WT and NM pools of the same
muscle ranged from 0.88 (DIA) to 0.97 (GAS and PLT). In
this instance, DIA again had the lowest correlation, suggesting
that not only does it differ from other muscle types, but that it
is also more profoundly affected by the expression of the
mutant protein. Noise intrinsic to DIA may partly contribute
but not fully explain these low inter-group correlations, as
the average correlation coefficient within the same group of
DIA specimens, be it WT or NM, was in both occasions
higher (0.91). Taken together, our analysis indicates that the pre-
sence of the mutant alpha-tropomyosin slow protein reduces
the dissimilarities in gene expression profile between muscles.
Significance analysis of microarrays
Significance analysis of microarrays (SAM) identified those
probe sets with significantly different expression between
NM and WT mice for each muscle type separately. The
same fold cutoff (þ1.5-fold change) and the same false dis-
covery rate (FDR) cutoff (12%) were applied to all muscles,
with the exception of EDL, where the lowest possible FDR
was 24%. Probe sets with more than one-third absent calls,
as determined by MAS5.0 (Affymetrix), were removed
(Materials and Methods). The numbers of significantly
changed probe sets, as well as their fold change, were
highly variable between different muscle types: TA ¼ 142
probe sets (fold-change range: 1.5–10.76), GAS¼8 (1.5–
2.73), DIA ¼ 1386 (27.74–6.68), PLT ¼ 36 (1.5–3.67) and
EDL¼4 (1.5–2.59) (Supplementary Material, Table S1).
DIA was the most affected muscle with more than 10 times
the number of significantly changed probe sets and a striking
number of under-expressed probe sets (1380 out of 1386 were
under-expressed in DIA as opposed to zero in other muscle
types). The major molecular pathways represented by those
probe sets are shown in Figure 2. It is also remarkable that
despite the prominent pathological changes in NM EDL
(12), only four probe sets met our statistical criteria for
change, suggesting that the magnitude and number of gene
expression changes in this muscle group was considerably
smaller than for the other muscles studied.
The lists of significantly changed probe sets for each muscle
were compared, to identify probe sets commonly changed
across all muscles and therefore likely to be highly related to
the presence of the mutant protein in a muscle-independent
manner. No probe sets were commonly changed across all five
muscles but two probe sets (97786_at and 103084_at representing
Ankrd2 and Csrp3, respectively) were common across
four muscles (excluding EDL). Two more probe sets were
common between TA, GAS and PLT (96167_at and 102213_at
representing Bag3 and Xin, respectively) and one probe set was
Figure 2. GO category analysis of genes considered significantly changed between WT and NM mouse muscles. All genes significantly changed in NM muscles
were grouped in GO biological process categories on the basis of the function of their respective proteins. This graph shows the major GO categories implicated
in each muscle studied when all significantly changed genes are considered. For DIA only, the top 200 significantly changed genes are tabulated. The results are
presented as (A) the actual numbers of significantly changed probe sets in each muscle type and (B) the percent of significantly changed probe sets for each
muscle type.











common between TA, DIA and PLT (103526_at, Padi2).
Overall, the most similarities were seen between TA and PLT
(19 probe sets), whereas at the other end of the spectrum, EDL
had no probe sets significantly changed in common with GAS,
DIA or PLT (Supplementary Material, Table S2).
All WT muscle types were compared with each other: the
largest number of differences was seen between DIA and all
other muscles (between 1435 and 2350 probe sets were signifi-
cantly changed), followed by TA versus EDL (696 probe sets)
and TA versus PLT (294 probe sets). All NM muscles were
also compared with each other: the largest number of differ-
ences was seen in DIA versus GAS (1118 probe sets), fol-
lowed by DIA versus TA (845 probe sets) and PLT versus
GAS (422 probe sets) (Fig. 3).
The lists of WT and NM muscle type-related differences
were compared and the significantly changed probe sets in
common were determined. In general, probe sets significantly
changed between WT muscles alone are likely to reflect
muscle-specific differences suppressed by the mutant
protein. Probe sets significantly changed between NM
muscles alone likely reflect differences promoted by the
mutant protein, i.e. muscle-specific responses to the mutant
protein. Probe sets common in the two lists likely represent inter-
muscle differences unaffected by the mutant protein. DIA
presented with the most differences at the WT inter-muscle
comparison level. However, NM DIA specimens had fewer
differences compared with other NM specimens. The same
pattern, although at a smaller scale, was true for all muscles
studied, with WT samples having more significantly changed
probe sets between them than the equivalent NM samples
(Fig. 3). Exceptional were the comparisons of PLT versus
GAS and EDL versus GAS, which showed the reverse pattern,
suggesting that the mutant protein triggers similar molecular
pathways across most, but not all muscles. Hence, the NM pro-
files were in general more similar than those for the WT muscles.
Evidence for increased satellite cell numbers and
immature fibers in nemaline muscles
Transcripts for genes reflective of myogenesis, Six4, Pcaf,
Myf6, Csrp3, Ankrd2, Tncc, Tnnt1, Tnni1, Mylpc and Lmna,
were elevated in one or more of the five NM muscles
analyzed. To determine whether this reflected an increase in
the number of satellite cells present in nemaline muscles, we
performed western-blot analysis of WT and NM TA muscles
using antibodies for proteins present in quiescent and/or acti-
vated satellite cells: MyoD, desmin, Pax7 and M-Cadherin.
Quantitative western-blot analysis showed that levels of
these proteins were elevated within the range of 1.6- to
2.66-fold (Fig. 4, Table 1). A similar trend was also observed
for the expression data of the respective genes (data not
shown). This was, however, below our analysis thresholds
for ‘significantly and highly’ changed. We also assessed the
number of Myf6 expressing nuclei in WT and NM muscle
to determine whether this indicator of immature muscle was
elevated in NM muscle. Immunohistochemical analysis of
the presence of My6 in myofiber nuclei as shown in
Fig. 5A–F revealed a 1.8-fold increase (34.2–62.5%,
P ¼ 0.005 by ANOVA) in the number of Myf6-expressing
myonuclei in NM TA muscle. Similarly, analysis of muscle
LIM protein expression (MLP; encoded by Csrp3), a factor
that promotes muscle differentiation, revealed marked differ-
ences in expression levels and intracellular localization
Figure 3. Numbers of significantly changed probe sets in pairwise comparisons
between the five different muscle types found (i) only in the WT versus WT
comparisons (‘WT’), (ii) only in NM versus NM (‘TG’) and (iii) in common
for both of these comparisons (‘COMMON’). Although WT DIA samples
exhibited many differences from other muscle types, far fewer significant
changes were seen in NM DIA comparisons with other muscle types.
Table 1. Quantitation of satellite cell content in nemaline muscle
Average density WT Average density NM Fold change
MyoD 226.5+ 34.9 404.1+ 33.6 1.8
Desmin 366.2+ 92.2 973.2+ 136.5 2.7
Pax7 75.4+ 7.7 179. 4+ 41.9 2.4
M-Cadherin 27.6+ 1.9 44.1+ 1.5 1.6
TA muscles from 2–3 WT or NM mice, 7–8 months of age, were ana-
lyzed 2–4 times each by western blot. The optical density of each
band was normalized to the corresponding Coomassie stained myosin
light chain band and the mean optical density determined for each
protein examined. Standard deviations were calculated and expressed
as + values of the mean density. Fold change was calculated from the
mean optical densities.
Figure 4. Western blot analysis of satellite cell markers, MyoD, desmin, Pax7
and M-Cadherin (M-Cad) (indicated at right) reveals elevations in aTmslow
(Met9Arg) transgenic TA muscle from 7–8-month-old NM mice. Two to
three replicate muscles from WT or NM mice were analyzed and a represen-
tative blot is shown. Control, Coomassie stained myosin light chain band.











between WT and NM TA muscles. Specifically, in WT TA
muscle, 12% of the peripheral myofiber nuclei displayed
prominent MLP expression, with a moderate cytoplasmic
signal in all fiber types. In contrast, 50% of the peripheral
nuclei in NM TA were MLP positive and 26% of the fast
fibers showed a significant over-expression of MLP in the
cytoplasm (Fig. 5G–L, a total of 400 nuclei and 250 fast
fibers were analyzed). In addition, in NM TA muscle, 7% of
the fibers had central nuclei and 90% of these were MLP
positive. Taken together, these observations reflect ongoing
fusion of satellite cells with existing myofibers and possibly
the maintenance of transcriptional activity reminiscent of
immature fibers.
Electron microscopic evidence for altered metabolism,
myofibrillar degeneration and focal repair in nemaline
muscles
Tissue specimens from DIA and TA of WT and NM mice
were used for electron microscopic (EM) analysis to identify
pathological features correlating with gene expression data.
Consistent with the gene expression profile, DIA demonstrated
a marked variation in the size and structure of subsarcolemal
mitochondria (Fig. 6A and B). Some mitochondria were sig-
nificantly larger than others, and mitochondrial structure
ranged from aberrant and variably shaped to partial lack of
cristae. This lack of cristae was concomitant with the presence
of vacuoles filled with material of medium electron density.
EM analysis of NM TA muscles revealed segmental degener-
ation of myofibers highlighted by the absence of sarcomeres
and the presence of mitochondria at different stages of
degeneration (Fig. 6C). Finally, cytoplasmic lipofuscin
inclusions, an indicator of oxidative stress, were encountered
in both tissues (data not shown).
Focal repair was evident in DIA and TA muscles as mani-
fested by the presence of centrally located nuclei in regions
or segments of myofibers (Fig. 6D). These myofibers did not
display overt signs of necrosis or degeneration, consistent
with a focal repair mechanism. Quantitation of fibers in
NM DIA and TA that contained centrally located nuclei or
Figure 5. Immunohistochemical analysis of Myf6 and MLP reveals increased expression in nemaline muscle. Myf6 (A–F) and MLP (G–L) were detected
immunohistochemically in TA muscles of 9- and 6-month-old, respectively, female WT (A–C, G–I) and NM (D–F, J–L) littermate mice. Small arrows indicate
representative Myf6 containing nuclei for (A–F) and representative MLP positive nuclei for (G–L). The TA muscles from NM mice have twice as many nuclei
expressing Myf6 (D–F) and four times as many MLP (J–L) containing nuclei compared with littermate controls (A–C and G–I, respectively). Furthermore, in
NM mice, unlike littermate controls, increased MLP staining was observed in the cytoplasm of multiple muscle fibers [large arrow heads in (J)]. All nuclei were
visualized using DAPI (stained blue in B, C, E, F, H, I, K and L). Scale bars ¼ 16.7 mm.











nuclei not at the periphery of the fiber revealed that 12%
of fibers in NM DIA and 7% of TA fibers exhibited
focal repair (Table 2). In the fibers of WT mice, nuclei
were only located at the periphery of the myofiber and mem-
brane ligatures, seen in NM muscles, were not observed.
DISCUSSION
Correlation coefficient analysis revealed that different nema-
line muscles had a considerably higher similarity between
them in terms of gene expression patterns than did the corre-
sponding wild-type muscles. This strengthens previous obser-
vations on the profound, naturally occurring differences in
gene expression between wild-type muscles (6,14–16), yet
more importantly, it indicates that the introduction of the
aTmslow(Met9Arg) mutation triggers similar disease-related
expression changes in the affected muscles. These results
suggest that a common pathophysiologic mechanism or
process is operating in nemaline muscles that have remarkably
different pathologies. The DIA, TA and GAS muscles of the
aTmslow(Met9Arg) mice have 50, 15 and 1% rod-containing
fibers, respectively (12), indicating that the process common
among nemaline muscles as revealed by gene expression
analysis is not related to the pathological feature characteristic
of the disease, i.e. nemaline rod formation.
In the present analysis of NM mouse muscles, gene
expression data revealed that transcripts reflective of myogen-
esis, muscle development and myofiber immaturity, such as
Six4, Pcaf, Myf6, Csrp3, Ankrd2, Tncc, Tnnt1, Tnni1, Mylpc
and Lmna, were elevated in one or more of the five muscle
types analyzed. The Six4 and Pcaf proteins regulate myogen-
esis through activation of myogenin and MyoD, respectively
(17,18), whereas MLP (encoded by Csrp3) and Myf6 are
essential and potent promoters of myogenesis (19,20).
Ankrd2, Tncc, Tnnt1, Tnni1 and Mylpc encode sarcomeric pro-
teins that participate in muscle development [Gene Ontology
(GO) classification]. Western-blot analysis confirmed the elev-
ated levels of M-Cadherin, MyoD, desmin and Pax7, classic
markers of satellite cells, suggesting increased numbers of sat-
ellite cells present in the mouse muscles. Furthermore,
increased numbers of Myf6-containing nuclei in myofibers
suggested relative immaturity of the muscle. Further direct
evidence of elevated focal repair in the DIA and TA
muscles was found by EM analysis (Fig. 6). These data are
further supported by our previous analysis of biopsies from
human NM patients, which demonstrated an increase in the
number of PAX7-positive muscle satellite cells, but no full
blown repair process (5). Interestingly, a previous study of
the response of these NM mouse muscles to chronic stretch
revealed that regeneration occurred with relative lack of cen-
tralized nuclei, a hallmark indicator of repair (21). Taken
together, these observations support the presence of ongoing
active, but focal, repair processes in nemaline muscle that is
not readily apparent by the classic indicator of muscle regen-
eration, extensive numbers of myofibers with centrally located
myonuclei as seen in the mdx mouse (4).
The majority of over-expressed muscle contraction-related
genes (such as Tncc, Tnnt1, Tnni1, Mylpc and Myh7), which
overlap to a large extent with the muscle development genes
mentioned earlier, coded for slow or cardiac muscle isoforms.
Although WT mouse muscles are fast fiber predominant, the
EDL muscle of aTmslow(Met9Arg) mice at 6 months of age
was shown to contain almost three times the number of
Table 2. Numbers and percentage of fibers with central nuclei in diaphragm
and tibialis anterior muscles of WT and aTmslow(Met9Arg) transgenic (NM)
mice
Diaphragm Tibialis anterior
WT NM WT NM
0/95 (0%) 11/92 (12%) 0/90 (0%) 7/94 (7%)
The location of nuclei within myofibers was used as an indicator of local
repair within the diaphragm and tibialis anterior muscles of wild-type
(WT) and nemaline (NM) mice. Fibers scored as having central nuclei
typically had only one nucleus within the field that was centrally
located. For a given muscle, total fibers were scored in 10 EM images
from each of three different muscles from mice of 7–8 months of age.
Parentheses indicate percentage of fibers with central nuclei.
Figure 6. EM analysis of aTmslow(Met9Arg) transgenic muscles reveals mor-
phological evidence for metabolic disturbance, myofibrillar degeneration and
repair in nemaline muscles. (A and B) Diaphragm of 8-month-old NM
mouse: enlarged, abnormally shaped and increased numbers of mitochondria
are present beneath the sarcolemma and in inter-fibrillar spaces. N, myonu-
cleus; M, mitochondria; (C) Tibialis anterior muscle of 8-month-old NM
mouse: myofibrillar degeneration is evident (arrowheads). Inter-fibrillar and
subsarcolemmal mitochondria display abnormal shape, size and number.
(D) Tibialis anterior muscle of 7-month-old NM mouse: localized repair is
evident by the presence of an isolated, centrally localized nucleus (asterisk)
within a myofiber.











slow/fast oxidative fibers than their WT littermates (12).
Furthermore, in the aTmslow(Met9Arg) mice, the relative
fiber-type content remained static with age, unlike their WT
littermates. Such an increase in numbers of slow fibers likely
explains the over-expression of slow muscle gene isoforms in
our gene expression data sets. The relatively static fiber-type
composition in the Tpm3 transgenic muscles, together with
the lack of slow/fast oxidative fiber number increase in a paral-
lel analysis of HSA-aTmslow(WT) transgenic mice (without the
Met9Arg mutation), supports earlier conclusions that the altered
muscle fiber-type content in the HSA-aTmslow(Met9Arg) mice
was due to the mutation and that the mechanism leading to this
phenotype might indeed be the disruption of normal muscle
maturation (12). The over-expression seen here for various
cardiac muscle isoforms (e.g. Mylpc and Myh7), which can be
expressed in skeletal muscle during the developmental stages,
may be indicative of both delayed maturation and regeneration.
Ankrd2 and Csrp3 are the only two genes consistently over-
expressed in four of the five muscles studied (fold-change
range Ankrd2 ¼ 2.7–8.6 and Csrp3 ¼ 2.3–5.5; Fig. 5G–L),
suggesting that this represents a key change in gene expression
induced by the presence of the mutant protein. Although both
Ankrd2 and Csrp3 are expressed predominantly in slow
muscle fibers, the level and extent of their over-expression
in all four out of five muscles in our study is beyond what
could be justified by the altered fiber-type content of the trans-
genic mouse muscles. Interestingly, the proteins encoded by
Ankrd2 and Csrp3 have a dual role by localizing both in the
nucleus and the sarcomere, participating in cell-cycle arrest,
initiation of muscle differentiation and/or sarcomere recruit-
ment (22–25). Over-expression of MLP (encoded by Csrp3)
has been associated with increased differentiation in C2C12
cells by enhancing the action of MyoD (26). Its localization
seems to change from nuclear to cytoplasmic with muscle
development, and changes in its localization can play a
crucial role in disease pathophysiology (27). Furthermore,
Ankrd2 and Csrp3 expression changes have recently been
described in several muscular dystrophies and myopathies,
although they did not pass the significance thresholds in our
human NM analysis (5,28–32). Csrp3 has been shown to
express significantly higher in WT TA (a representative of
distal muscles) than quadriceps (a representative of proximal
muscles) in WT mice (30). Despite potential gene expression
differences between the five different WT muscles
studied, significant Csrp3 expression changes were induced
in 4 muscles, including three of four distal muscles and DIA.
Increased expression of neurogenesis-related genes (Cited2,
Enah, Pten, Dctn1 and Wfs1) was also detected in the transgenic
mice. The majority of these genes, such as Enah and Cited2
(33,34), are primarily involved in prenatal development. Their
increased expression in the 7–10-month-old HSA-aTmslow
(Met9Arg) mice further supports an ongoing repair process.
Over-expression of myogenesis/muscle development genes
was seen in all five muscles and neurogenesis in three (TA,
PLT and EDL). However, the number of significantly
changed genes and their fold change was higher in TA than
in GAS, PLT, EDL and DIA (number of genes¼ TA: 9, all
others: 2–6; fold change¼ TA: 1.5–10.7, all others: 1.5–6.7).
In contrast to our previous findings on human NM speci-
mens, where the glycolytic energy production pathway was
significantly down-regulated, the HSA-aTmslow(Met9Arg)
mouse muscles TA, PLT, EDL and GAS exhibited no major
changes in the expression of genes encoding the proteins
involved in metabolic pathways. DIA, however, presented
with a prominent down-regulation of over 25 inner mitochon-
drial membrane oxidoreductase genes (fold change 21.5
to 27.5). These are known to be involved in mitochondrial
ATP production. Strongly supportive of these gene expression
observations were EM findings of marked mictochondrial size
and shape variation in DIA (Fig. 6A and B). Structural vari-
ation was also evident with some mitochondria lacking
cristae but having vacuoles filled with material of medium
electron density. It, therefore, seems likely that energy pro-
duction defects (as seen at the gene expression level) are sec-
ondary changes associated with more severe stages of NM
such as exhibited by DIA and the majority of human patients
previously studied by microarrays (5,35).
Atp2a2 and Casq2, two proteins responsible for transporting
and storing calcium ions, respectively, in the sarcoplasmic
reticulum of cardiac and slow skeletal muscles, were
up-regulated at the gene expression level in the transgenic
TA (Atp2a2 and Casq2) and PLT (Atp2a2 only) muscles. In
our previous study of NM patients, their human orthologs
were also significantly changed (ATP2A1 ¼24.1-fold;
CASQ2 ¼ 2.8-fold) together with several other calcium
homeostasis-related genes (5). These were two of the few
genes commonly changed in both species, suggesting a poss-
ible close link to the disease pathogenesis. The opposite direc-
tions of the ATP2A1 and Atp2a2 fold changes, together with
the variability in fiber-type percentages of human specimens
(six had slow-fiber predominance, three had fast-fiber predo-
minance and four were normal), suggest that calcium
homeostasis-related gene expression changes are likely to
reflect the frequent slow-fiber predominance as seen in the
case of the over-expressed slow-fiber isoforms Atp2a2,
Casq2 and CASQ2 and the under-expressed ATP2A1. Consist-
ent with this hypothesis, mechanical studies addressing the
response of individual fibers to calcium ions did not find any
changes in HSA-aTmslow(Met9Arg) mice (12).
Increased expression was also evident for a number of
transcription, translation and protein modification genes
such as Pdlim1, Atf5, D11Ertd619e, Eif4bp1 and Rpl22
(fold change 1.51–3.00). Indirectly, this evidence suggests
an increase in overall transcription/translation/protein syn-
thesis in the transgenic TA, PLT and GAS muscles.
Apoptosis- and proteolysis-related genes (such as Faf1,
Pdcd7, Dffa, Bcl2l11, Bag3 and Traf3) were also over-
expressed in TA, PLT, GAS and EDL (fold change 1.5–2.1).
It is difficult to speculate on the order of cellular events
based on the present data. However, given the parallel
increase in myo/neurogenesis, transcription, protein biosyn-
thesis, apoptosis and proteolysis, we hypothesize that different
cell populations are present in the transgenic muscles, with
some cells going through a developmental phase and others
undergoing proteolysis and apoptosis: consistent with a
model involving some degree of regeneration. In support of
this hypothesis, EM studies on TA revealed segmental
degeneration of myofibers together with small areas of regen-
erating fibers, manifested by the presence of centrally located
nuclei in small myofibers.











In all of the analyses performed, DIA consistently presented
with the most pronounced transcriptional differences in
comparison with those observed in the TA, PLT, GAS and
EDL muscles. Not only was the number of significantly
changed genes in the transgenic DIA 10–100-fold greater
than that in the other muscles examined, but their functions
and overall direction of change (99.6% probe sets were
under-expressed in NM DIA) were markedly different
(Supplementary Material, Table S1). Furthermore, the
overall transcriptional profile of the NM DIA was more
similar to the various WT limb muscles than to WT DIA
(Fig. 1). Diaphragm has been shown to have a unique
pattern of gene expression, relative to other skeletal muscles
(6,16). Many of the 1386 significantly changed probe sets in
the WT versus NM DIA comparison represent non-muscle
transcripts that may reflect a relative absence or loss of
increased vascularity and/or other functional specializations
of the diaphragm (Supplementary Material, Table S1)
(unpublished data). The functional categories of genes with
highest expression differences between NM and WT DIA
included metabolism, especially protein, lipid and organic
acid metabolism, followed by cell growth. The latter consisted
almost exclusively of transport-related genes. We hypothesize
that these data reflect a relative lack of specialization of NM
DIA muscles in HSA-aTmslow (Met9Arg) mice. Thus, the
presence of the mutant protein appears to disrupt the skeletal
muscle maturation process, with a more dramatic effect in
the case of DIA.
The differential response of DIA compared with other skel-
etal muscles has also been described in the mdx mice (16,36).
Similar to our findings, mdx DIA was more severely affected
than other skeletal muscles, with a profound metabolic crisis
reflected predominantly by the down-regulation of numerous
mictochondrial transcripts. Unlike aTmslow(Met9Arg), mdx
DIA showed a marked up-regulation of most differentially
expressed transcripts. Furthermore, a number of other
dystrophy related molecular pathways were more severely
affected in mdx DIA, including regeneration, inflammation
and fibrosis (16). Regardless of the disease, DIA appears to
have pathophysiological mechanisms distinct from other
skeletal muscles.
DIA data sets also had weaker correlations between them,
both in the WT and the NM groups (average r ¼ 0.91, as
opposed to 0.95–0.97 seen for other muscles). Although the
physical location of this muscle could give rise to concerns
regarding the cellular purity of the samples used, our long
experience in dissecting such muscles together with previous
evidence showing the highly variable expression of DIA com-
pared with other muscles points to the accuracy of these
measurements (16,36). The increased difference between
WT and NM DIA could be associated with the somewhat
higher levels of aTmslow(Met9Arg) protein detected in this
muscle, although sensitivity limitations in western-blot
analysis preclude a definite association (12).
In conclusion, the lists of significantly changed genes
between the different transgenic mouse muscle types varied
considerably, yet there was a substantial overlap in the func-
tional pathways affected by the mutant protein, and particu-
larly muscle development. It is important to remember that
some of these changes could be related to Tpm3 being overex-
pressed, and therefore, further studies comparing our findings
with new NM mouse models are warranted. To a large extent,
these molecular processes also overlap and extend our
previous observations on human NM muscle specimens. The
consistent finding of evidence for a repair process, character-
ized by some degree of degeneration and regeneration, in
both species indicates that this is a basic aspect of NM patho-
physiology. These findings reveal a novel feature of NM that
has previously been considered uncharacteristic of congenital
myopathies.
MATERIALS AND METHODS
Mouse samples and microarray experiments
Five different mouse skeletal muscles were studied from
normal FVB/NJ and transgenic mice expressing an autosomal
dominant mutant of alpha-tropomyosinslow under the HSA
promoter (HSA-aTmslow(Met9Arg)) (12). All five muscles
had similar levels of aTmslow protein expression but variable
rod content (Supplementary Material, Table S3) (37,38).
Three to four replicate total RNA pools were generated for
each muscle type (TA, GAS, PLT, DIA and EDL). Each
pool originated from muscle specimens of three to five mice.
These specimens were obtained at the age of 7–10 months
and were snap frozen.
RNA extraction (6–8 mg from each tissue sample), target
preparation and hybridization to Affymetrix U74Av2 Gene-
Chips were performed as previously described (5). The
U74Av2 GeneChip contains 12 488 annotated genes and
ESTs. The 36 raw data sets are publicly available at http://
www.ncbi.nlm.nih.gov/geo/, under the series code GSE3384.
Data analysis
The 36 data sets (3–4 pools  five muscle types  normal and
transgenic) were first processed by the Affymetrix MAS5.0
software, which computed the signal values (reflecting
expression levels) and ‘present/absent’ calls (an Affymetrix
computed measure representing confidence in gene expression
presence) for each probe set. The signal values were adjusted
to an overall target intensity of 1500 but were not normalized
at this stage.
For correlation coefficient analysis, r-values for overall gene
expression were calculated for all 36 data set pairwise com-
parisons. We then calculated the average of the r-values for
the data sets of each specific muscle type (five muscles) and
state (transgenic and wild-type). As a third step, we calculated
the r of each muscle/state versus all others (Fig. 1).
SAM was used to identify significant fold changes between
WT and NM specimens as described (39). Prior to this analy-
sis, all data sets were normalized to a slope of 1, with the data
set having the highest correlation to all others (PLTn2). For
each muscle type, a two-class unpaired data analysis was per-
formed comparing NM with WT specimens, using a fold
threshold of 1.5 [where fold is calculated as: (average
expression in NM specimens)/(average expression in WT
specimens)] and a FDR cutoff of 12.5%. Because no genes
were significantly changed for EDL samples at these
thresholds, we present the four probe sets significantly











changed at the lowest FDR available (24.9%). All significantly
changed probe sets were assessed for present/absent calls and
only those with 1/3 present calls were included in further
analysis. SAM analysis was repeated to compare (i) the differ-
ent WT muscle types and (ii) the different NM muscle types,
using the same fold and FDR thresholds as earlier.
Immunohistochemistry
TA muscles from transgenic nemaline and littermate control
mice were transversely sectioned at 5 mm thickness, placed
onto polysine-coated microscope slides (Biolab Scientific)
and fixed in 4% formaldehyde for 5 min. Slides were
blocked and permeabilized in a mixture of 1PBS, 0.2%
fish gelatin and 0.1% Triton X for 1 h at RT. Sections were
incubated in a rabbit polyclonal Myf6 primary antibody
(Santa Cruz, SC301 C-19; 1:200 dilution) for 1 h at RT. The
sections were washed thoroughly and incubated in an Alexa
Fluor 555 goat anti-rabbit secondary antibody (Molecular
Probes; 1:1000 dilution) for 1 h at RT. Nuclei were detected
by co-staining sections with DAPI (Sigma; 0.4 mg/ml) for
5 min and a final 5 min wash in 1PBS. Images were captured
using a digital camera at 20 magnification and merged using
Spot advanced program. Nuclei expressing Myf6 were scored
using the Image-Pro software (Media Cybernetics, Silver
Spring, MD, USA).
Immunohistochemistry for MLP (the Csrp3 gene product)
was performed as previously described (5) using chicken poly-
clonal Csrp3 primary antibody (Abcam; 1:100 dilution) for
2.5 h at RT and Alexa Fluor 594 goat anti-chicken secondary
antibody (Molecular Probes; 1:200) for 1 h.
Western blotting
Skeletal muscle tissue was homogenized in 20 volumes lysis
buffer (25 mM Tris pH 7.8, 2 mM EDTA, 10% glycerol, 1%
Triton-X 100, 1.5 mM MgCl2, 200 mM NaCl and 10 mM
PMSF). Frozen samples were firstly crushed with a pestle
and then resuspended in the lysis buffer in an Eppendorf
tube. Samples were allowed to sit on ice for 1 h with constant
resuspension, followed by centrifugation at maximum speed
for 5 min at 48C. The supernatant was saved. Samples were
stored at 2208C. Equal volumes of protein were analyzed
on 12.5% SDS–PAGE gels. Protein was transferred onto
PVDF membranes (Millipore) for 1 h at 10 V using the
Biorad semidry transblot. Blots were blocked overnight at
48C in 5% skim milk in Tris-buffered saline containing
0.1% Tween-20 (TBST), washed in TBST and incubated
with antibody overnight at 48C (MyoD: Santa Cruz, M318;
Desmin: NOVOcastra, NCL-L-DES-DERII; M-Cadherin:
Santa Cruz, SC10734; Pax7: Developmental Studies Hybri-
doma Bank), followed by three washes with TBS 0.1%
Tween-20. HRP-labeled secondary antibody was added at a
1:10 000 dilution for 1 h at RT. Excess antibody was
removed with 4  20 min washes. Detection was performed
using the western lightning chemiluminescence detection
system (Perkin Elmer) on Fuji RX film for varying times
(2–60 min).
Electron microscopy
Muscles were removed from anaesthetized mice and immedi-
ately cut into very thin slices while immersed in modified
Karnovski’s fixative (2.5% glutaraldehyde/4% paraformalde-
hyde in 1 M cacodylate buffer, pH 7.4). Samples were
further fixed overnight in the same fixative and post-fixed
with 2% osmium tetroxide, dehydrated through an ascending
series of ethanol and embedded in Spurr’s epoxy resin. Ultra-
thin sections (70 nm) were cut with a Reichert-Jung ULTRA-
CUT ultramicrotome, double contrasted with uranyl acetate
and lead citrate, viewed and photographed with a Philips
CM120 BioTwin transmission EM.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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